Arcutis Biotherapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
On December 13, 2024, Patrick Burnett, our Chief Medical Officer, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 177,732 shares of Common Stock held by Mr. Burnett between March 11, 2025 and February 27, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.